LANCET INFECT DIS:1990 - 2015全球和区域HIV-1分子流行病学特征

2019-02-02 MedSci MedSci原创

HIV-1<span style="font-family:宋体; mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: 宋体;mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Calibri; mso-

HIV-1基因全球多样性是开发HIV疫苗面临的重大挑战。本研究的目标是估计1990 - 2015年期间HIV-1亚型和重组体的区域和全球分布情况。通过一项全球调查收集了更多未发表的HIV-1分型数据。研究纳入了1990 - 2015年收集的HIV-1分型数据的流行病学研究。将国家分为14个区域,并分析了4个时间段(199099年、200004年、200509年和201015)的数据。根据联合国艾滋病规划署对每个国家艾滋病毒感染(PLHIV)数量的估计,对各国艾滋病毒1型、循环重组形(CRFs)和独特重组形(URFs)的分布情况进行加权,以生成每个时间段艾滋病毒1亚型多样性的区域和全球估计。主要结果是确定为HIV-1亚型ABCDFGHJKCRFsURFs的样本数量。该系统综述在普洛斯彼罗注册,编号为CRD42017067164

该系统综述和全球调查在1990年至2015年间获得了2203个数据集,其中383 519个样本来自116个国家。201015年,全球所有HIV-1感染中,C亚型占46.6% (16 280 897/34 921 639 / PLHIV)B亚型导致12.1%(4 235 299/34 921 639)的感染,其次是A亚型(10.3%)3 587 003/34 921 639) CRF02_AG(7.7%;2 705 110/34 921 639) CRF01_AE(5.3%;1 840 982/34 921 639) G亚型(4.6%;1 591 276/34 921 639) D亚型(2.7%;926 255/34 921 639)FHJK亚型合计占感染的0.9%(311 332/34 921 639)。其他CRFs3.7%(1 309 082/34 921 639),使所有CRFs的比例达到16.7%(5 844 113/34 921 639)URFs占全球HIV-1感染总数的6.1%(2 134 405/34 921 639),重组型占全球HIV-1感染总数的22.8%(7 978 517/34 921 639)HIV-1亚型和重组体的分布随时间在国家、区域和全球发生变化。在2005 - 15年的全球水平上,B亚型增加, AD亚型稳定, CG以及CRF02_AG亚型下降。CRF01_AE、其他crfURFs增加,导致重组型的整体比例随时间持续增加。全球和区域艾滋病毒多样性是复杂的和不断演变的,是艾滋病毒疫苗开发的一大挑战。监测艾滋病毒1型的全球分子流行病学对艾滋病毒疫苗的设计、检测和实施仍然至关重要。

原始出处:

Joris Hemelaar, DPhil, Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012935, encodeId=b8e12012935d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 30 13:47:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033131, encodeId=eec12033131cf, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Feb 12 22:47:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829941, encodeId=6589182994106, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 09 00:47:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411318, encodeId=d157141131839, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Feb 04 00:47:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012935, encodeId=b8e12012935d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 30 13:47:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033131, encodeId=eec12033131cf, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Feb 12 22:47:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829941, encodeId=6589182994106, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 09 00:47:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411318, encodeId=d157141131839, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Feb 04 00:47:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012935, encodeId=b8e12012935d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 30 13:47:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033131, encodeId=eec12033131cf, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Feb 12 22:47:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829941, encodeId=6589182994106, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 09 00:47:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411318, encodeId=d157141131839, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Feb 04 00:47:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2019-12-09 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012935, encodeId=b8e12012935d8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Nov 30 13:47:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033131, encodeId=eec12033131cf, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Feb 12 22:47:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829941, encodeId=6589182994106, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 09 00:47:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411318, encodeId=d157141131839, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Mon Feb 04 00:47:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2019-02-04 xugumin

相关资讯

2016年12月16日Science期刊精华

本周又有一期新的Science期刊(2016年12月16日)发布,它有哪些精彩研究呢?让小编一一道来。 1.Science:拟南芥的抗菌防御机制---调节糖转运体的活性 doi:10.1126/science.aah5692; doi:10.1126/science.aal4273 细菌依赖糖茁壮成长。植物细胞也是如此。如今,Kohji Yamada等人证实当致病性细菌入侵植

NEJM:东非和泰国成人急性HIV-1感染研究

急性人类免疫缺陷病毒1型(HIV-1)感染是传播HIV-1的主要原因,了解认识急性HIV-1感染有助于根除HIV-1或实现功能性治愈的治疗策略的发展。 研究者对2276名 HIV-1感染高危者每周进行两次定性血浆HIV-1 RNA核酸检测。对检测到HIV-1 RNA核酸的参与者,进行临床观察,定量检测HIV-1 RNA水平、HIV抗体和淋巴细胞的免疫分型结果(每周两次)。 研究结果显示

NATURE:HIV-1抗体的联合治疗维持病毒长期抑制

在具有抗体敏感性病毒储库的个体中,抗HIV-1单克隆抗体3BNC117和10-1074的组合可以在没有抗逆转录病毒疗法的情况下维持HIV-1长期抑制

NAT MED:HIV-1抗体组合在病毒血症患者中的安全性评估

最近,来自洛克菲勒大学的研究人员报告了一个1b期临床试验(NCT02825797)结果,其中两个有效的bNAb,3BNC11713和10-107414,被组合给予七个HIV-1病毒血症个体。

PloS Pathogens:研究模拟HIV-抗体相互作用,优化HIV治疗!

实验和数学分析揭示了HIV-1和抗体之间相互作用的新见解,可以抑制病毒从一个人传播到另一个人。在PLOS病原体中提出的这些发现可能有助于开发用于HIV-1的新的治疗方法和疫苗。

PLOS ONE:天花疫苗能否影响女性HIV-1易感性?

1980年全球停止接种天花疫苗。最近的研究表明,与不接种天花疫苗的女性相比,接种天花疫苗的女性感染艾滋病毒风险降低。